

Reference:	FOI.4492.20
Subject:	Anti-Vascular Endothelial Growth Factor therapy treatments for eye conditions
Date of Request:	11 November 2020

Requested:

1. Within your trust how many patients over the last 12 months (November 2019 to October 2020 or latest available) have received the following anti-VEGF treatments:
 - Aflibercept
 - Bevacizumab
 - Brolucizumab
 - Dexamethasone
 - Fluocinolone acetonide
 - Ranibizumab
2. For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.
 - Aflibercept
 - Bevacizumab
 - Brolucizumab
 - Dexamethasone
 - Fluocinolone acetonide
 - Ranibizumab

Response:

1. Hywel Dda University Health Board (UHB) provides, within the table below, the number of patients that received the anti-VEGF treatments listed, for the period, November 2019 to October 2020, as requested.

Treatment	Number of patients
Aflibercept	3,764
Bevacizumab	0
Brolucizumab	0
Dexamethasone	22
Fluocinolone acetonide	0
Ranibizumab	5,995

2. The UHB provides, within the table below, the number of first time patients that received the anti-VEGF treatments listed, for the period November 2019 to October 2020, as requested.

Treatment	Number of patients
Aflibercept	139
Bevacizumab	0
Brolucizumab	0
Dexamethasone	13
Fluocinolone acetonide	1
Ranibizumab	275